Lab & Pathology Billing - Stop Leaving Tested Revenue Behind

Avoidable Pitfalls in Laboratories Pathology Billing

Bundled Panels Are Erasing Tests You Actually Ran

Lab panels bundle together in specific ways depending on which components you ran and which payer you're billing. Get the bundling rules wrong and legitimate, separately performed tests disappear into a denied claim.

A Missing Medical-Necessity Box Can Turn Into a Fraud Audit

National and Local Coverage Determinations set strict medical-necessity rules that vary by test and by payer. Miss one and you're not just facing a denial - you're facing the kind of documentation gap that triggers a compliance audit.

High-Complexity Testing Sits in Prior-Auth Limbo Longer Than You'd Expect

Molecular and genetic tests carry some of the most demanding prior-authorization requirements in lab billing, each requiring detailed clinical documentation before it's even submitted. That paperwork burden is exactly where payment gets stuck.

Toxicology Testing Gets Extra Scrutiny - and Extra Denials

Toxicology billing draws more payer scrutiny than almost any other lab category, with specific limitations on frequency and documentation. Without lab-specific expertise, that scrutiny turns into denials.

Pathology Reads Get Paid Less When the Components Aren't Split Correctly

Surgical pathology and cytology interpretation involve a technical component and a professional component that have to be billed separately and correctly. Collapse them together and you're leaving part of the reimbursement on the table.

Manual Order Entry Is Where Lab Errors Actually Start

Electronic orders, accession numbers, and result reporting move across multiple systems before a claim is ever generated. Every manual touchpoint in that chain is a chance for an error that shows up later as a denial.

How We Tighten Laboratories Pathology Claims

Lab Billing Handled by a Dedicated Team

With laboratory and pathology specialists on your claims, each panel, specimen, and interpretation goes out correctly the first time - so more of what you run actually gets paid.

• Panels and separate specimens captured at their full value
• Fewer denials from bundling and component errors
• Coverage rules tracked so appropriate tests aren't rejected
• Faster, cleaner payment on the work your lab already did

Medical-Necessity Review That Protects You From Audits

We check test orders against payer coverage rules before the claim goes out, so appropriate testing gets paid and the documentation gaps that trigger audits never open.

• Orders matched to the diagnoses that support payment
• Patient financial-responsibility paperwork handled when required
• Lower audit exposure on high-scrutiny testing
• Fewer write-offs from preventable necessity denials

Prior Authorization for Genetic and Molecular Testing

Our authorization desk clears high-complexity genetic and molecular tests before you run them, with the clinical justification payers actually require submitted upfront.

• Approvals secured before expensive tests are performed
• Clinical documentation prepared and submitted for you
• Every request tracked so nothing stalls unnoticed
• Higher approval rates and fewer costly reruns

Order-to-Claim Accuracy

We connect your lab systems so orders, specimens, and results flow into clean claims without the manual re-entry where errors start.

• Less manual data entry and fewer downstream denials
• Specimens tracked from accession through billing
• Claims generated cleanly from your existing systems
• Real-time visibility into where each claim stands

Managed Laboratories Pathology Revenue Cycle

Clinical Laboratory Billing

Expert billing for routine and specialized clinical lab tests including chemistry, hematology, and microbiology.

• Chemistry panel billing
• Hematology testing
• Microbiology cultures
• Immunology assays

Molecular Diagnostics

Specialized billing for molecular testing including genetic panels, PCR, and next-generation sequencing.

• Genetic panel billing
• PCR testing
• NGS procedures
• Oncology molecular testing

Toxicology Billing

Compliant billing for drug testing and toxicology screening with proper documentation and limitations.

• Drug screening
• Confirmation testing
• Therapeutic drug monitoring
• Pain management testing

Pathology Services

Complete billing for surgical pathology, cytology, and anatomic pathology services.

• Surgical pathology
• Cytology interpretation
• Immunohistochemistry
• Flow cytometry

Frequently Asked Questions

What makes laboratory and pathology billing unique?

Laboratory and pathology billing is unique because: (1) it's high-volume and low-dollar - labs process hundreds to thousands of claims a day at roughly $5 to $200 per test, so a tiny per-claim error is invisible individually but catastrophic at scale (a $4 error across 800 claims a day is about $960,000 a year); (2) every test needs a diagnosis that meets the specific national or local coverage criteria for that test, or it's denied; (3) billing a full panel versus its individual components can swing reimbursement 25-40%; (4) the PAMA fee schedule has cut clinical lab reimbursement roughly 10-15% since 2018 based on private-payer rate reporting; (5) labs must obtain advance beneficiary notices before non-covered tests or absorb the cost; and (6) reference labs have to manage both patient/payer billing and client (physician-office) billing for referred specimens. At lab volumes, disciplined medical-necessity and panel-vs-component decisions are the difference between margin and loss.

What makes pathology billing complex?

Pathology billing complexity: (1) Specimen-based billing - pathology is billed per specimen, not per slide or per test, so specimens received must be carefully correlated to what is billed, (2) Technical and professional components - surgical pathology can be split into the technical (equipment/lab) and professional (interpretation) components depending on where the service is performed, (3) Specimen-level assignment - each specimen must be assigned to the correct complexity level based on the tissue type, and mis-leveling directly changes reimbursement, (4) Special stains and immunohistochemistry - these are add-on services billed per stain or per antibody, (5) Molecular pathology - molecular testing carries rapidly evolving codes and coverage criteria, (6) Cytopathology - Pap-smear billing differs for manual vs automated screening and for physician interpretation, and (7) Consultation services - pathology consultations with slide review have their own coding. The core risk is leaving revenue on the table by under-leveling specimens or missing add-on stains.

How do you assign the correct surgical pathology level?

Surgical pathology is billed by complexity level, and the level is driven by the type of tissue received - not by the clinical diagnosis - which is the single most misunderstood point. **The levels climb by complexity:** gross examination only; gross and microscopic (for example, an incidental appendix or hernia sac); low complexity (gallbladder, prolapse uterus, skin cyst excision); moderate complexity, which is the most common level and covers skin biopsies, colon biopsies, thyroid lobectomy, lymph node biopsy, prostate needle biopsy, and cervical biopsy; high complexity (lung lobectomy, partial or total nephrectomy, uterus with tumor, non-needle liver biopsy); and the highest complexity (bone marrow biopsy with cellularity assessment, fetal organs, exenteration specimens). **The rule that drives revenue:** each specimen is billed separately at its own appropriate level, and the level is set by the tissue itself. Three separate skin biopsies are three separately billed moderate-complexity specimens, not one. Assigning the level by tissue type and billing per specimen is what makes pathology revenue both accurate and defensible.

What are the most common lab billing denials?

Top laboratory denials: **Medical Necessity:** The #1 lab denial - the diagnosis on the requisition does not match the payer's coverage criteria for the ordered test. Prevention: automated diagnosis-to-test validation before the test is performed. **Panel Bundling:** Individual components billed when a single panel applies, or a panel billed when not all its components were performed. **ABN Missing:** A non-covered test performed without obtaining an Advance Beneficiary Notice - the lab absorbs the cost and can't bill the patient. **Molecular Test Authorization:** Genetic and molecular tests denied at 2-3x the rate of routine tests due to missing prior authorization, narrow coverage policies, or insufficient documentation. **Duplicate Testing:** The same test billed twice on the same date of service, or repeat testing within payer frequency limits. **Distinct-Test and Waived-Test Flags:** Missing the documentation that identifies genuinely separate tests, or the flag for CLIA-waived point-of-care tests.

What are common pathology billing denials?

Top pathology denials: **Specimen Level Errors:** Billing at the wrong specimen-complexity level - upcoding a simple skin biopsy to a higher level, or downcoding a needle biopsy that warrants a higher one. **IHC Medical Necessity:** Immunohistochemistry denied without a documented clinical indication - the record must show how the results will change the diagnosis or treatment. **Molecular Test Coverage:** Molecular pathology denied under narrow coverage policies - verify coverage before performing expensive molecular testing. **Duplicate Specimens:** Billing multiple specimens for fragments from the same anatomic site that should be accessioned as one. **Consultation Billing:** Intradepartmental consultation denied when the referring and consulting pathologist are in the same group practice. **Cytopathology Method:** Billing a liquid-based Pap when a conventional Pap was performed, or billing physician interpretation when automated screening was used.

What are compliance risks in laboratory billing?

Lab compliance risks: (1) Medical necessity validation - ordering tests without qualifying diagnoses is the #1 lab compliance issue; implement automated diagnosis-to-test edits before performing tests, (2) Panel unbundling - breaking apart complete panels into individual components to increase reimbursement constitutes fraud, (3) Reflexive testing - automatically performing additional tests without a physician order or standing order protocol violates medical necessity rules, (4) Kickback arrangements - providing free specimen collection supplies, couriers, or phlebotomy services to referring physicians in exchange for referrals violates the Anti-Kickback Statute, (5) Self-referral (Stark Law) - physician ownership in clinical labs must meet specific exceptions, (6) ABN compliance - performing non-covered tests without ABNs and then billing patients creates financial liability for the lab, and (7) Specimen integrity - billing for results from specimens that do not meet collection or handling standards compromises both quality and compliance.

Breaking Down Laboratories Pathology Reimbursement

Why Anatomic and Clinical Work Get Paid Differently

Laboratories and pathology groups earn revenue in two very different ways, and the money leaks when they're treated the same. Anatomic pathology - the pathologist reading slides and specimens - is paid partly for the physician's interpretation and partly for the technical work of preparing the specimen, and those two halves have to be billed correctly, especially when your pathologist reads slides prepared by an outside lab.

Clinical testing of blood, fluids, and cultures is paid off a separate fee schedule entirely. A frequent source of lost anatomic revenue is collapsing multiple distinct specimens into one charge: when several separate specimens come from the same patient on the same day, each one is its own billable service at its own level of complexity, and each added stain a pathologist applies is separately payable when it's documented individually. Bill it as one lump and the practice quietly gives away the reads it actually performed.

• Bill each separate specimen at its own complexity level - don't fold several specimens into one charge
• The pathologist's interpretation and the technical preparation are paid separately; both halves have to be captured
• When your pathologist reads slides from an outside lab, the interpretation is billed on its own
• Each additional stain applied to a specimen is separately payable when documented individually

Cytology and Fine-Needle Aspiration: Two Bills, Not One

Fine-needle aspiration is one of the easiest places for a lab to lose money, because two different providers are usually owed for one patient encounter. The clinician who performs the aspiration is paid for the procedure itself, while the pathologist is separately paid for evaluating what was collected - and when the pathologist is physically present to confirm on the spot that the sample is adequate, that on-site assessment is its own billable service.

If your pathologist provides that on-site read but it never reaches the claim, you're giving away work that was already done at the bedside. Pap and related screening work carries its own trap: the amount you're paid depends on how the sample was collected and prepared, and when additional screening is run on the same sample it needs its own supporting reason on the order, or the payer strips it off.

• The aspiration procedure and the pathologist's evaluation are two separate bills for one encounter
• On-site adequacy checks by the pathologist are separately payable - capture them when they happen
• How a Pap sample is collected and prepared changes what you're paid - match the charge to the method
• Additional screening run on the same sample needs its own documented reason or the payer won't cover it

Genetic and Molecular Testing: Get Approval Before You Run It

Genetic and molecular testing is the highest-dollar, highest-risk work most labs do, and it's where cash disappears fastest when the front-end paperwork isn't handled. Nearly every commercial payer now requires prior authorization for genetic panels and genomic profiling before the test is performed, with clinical justification submitted upfront - run the test first and hope for payment later, and you're gambling thousands of dollars per case on an approval you may never get.

Medicare adds its own layer: many molecular tests aren't covered at all unless the specific test is registered and identified the way the program requires before the claim goes in, and proprietary lab-developed tests are covered on a payer-by-payer basis. The labs that get paid for this work treat authorization and coverage verification as a gate the specimen passes through before testing, not a problem to sort out after the result is already reported.

• Genetic panels and genomic profiling need prior authorization with clinical justification submitted before testing
• Verify each test's coverage upfront - the most complex, highest-value work is exactly what payers scrutinize hardest
• Many molecular tests aren't covered unless the specific test is properly registered and identified before billing
• Proprietary lab-developed tests are covered payer by payer - confirm coverage before you run them, not after

The Requisition Decides Whether You Get Paid

In lab billing, the diagnosis on the requisition matters as much as the test result. Payers publish coverage rules, and Medicare formalizes them through national and local coverage determinations, that spell out which diagnoses justify which tests. The lab doesn't control that diagnosis; the ordering provider writes it, and if it doesn't meet the coverage criteria for the test ordered, the claim is denied even when the testing was clinically appropriate.

The lab ran the work and the lab eats the loss. The answer isn't calling every ordering office to argue about diagnoses. It's checking each requisition against the applicable coverage rules before the specimen is run, so a mismatch gets resolved while there's still time: the ordering provider clarifies the diagnosis, or the patient signs the notice accepting financial responsibility.

That notice only protects you if it's signed before testing; a form obtained after the fact is worthless, and for referred specimens the patient isn't even in your building, which is why the check has to happen at accessioning, not at billing.

• The ordering provider's diagnosis, not the test itself, determines whether the payer considers the test necessary
• Screen every requisition against coverage rules before the specimen is run, not after the claim denies
• Patient financial-responsibility notices must be signed before testing; a retroactive form is invalid
• Referred specimens need the coverage check at accessioning, while the ordering office can still fix the diagnosis

Small Errors, Multiplied by Thousands of Claims

A physician office that misbills one visit loses one visit's worth of revenue and usually notices. A lab that misbills one test type loses a few dollars per claim and rarely notices, because the same error rides silently on hundreds of claims a day, week after week. At lab volumes, a per-claim leak too small to flag individually adds up to a material share of annual collections.

Fee-schedule pressure makes this worse: federal law now ties Medicare's clinical lab fee schedule to the private-payer rates labs report, which has pushed reimbursement on routine high-volume testing down substantially, and many commercial plans benchmark their own rates to it. When the underlying rate is already compressed, billing accuracy is one of the few levers a lab still controls.

The practical response is denial and underpayment analysis by test category rather than by individual claim, so a systematic pattern surfaces as a pattern and gets fixed at the root instead of appealed one claim at a time.

• Per-claim errors too small to notice individually become large annual losses at lab volume
• Medicare's lab fee schedule is now tied to reported private-payer rates, and commercial plans often benchmark to it
• With rates compressed, billing accuracy is one of the few margin levers a lab still controls
• Analyze denials and underpayments by test category so systematic patterns get root-cause fixes, not one-off appeals

Referred Specimens: Who Bills Whom Matters as Much as the Test

When specimens arrive from physician offices, hospitals, or other labs, the billing arrangement determines both your margin and your legal exposure. Bill the patient's insurance directly and you keep the full contracted rate but absorb all denial risk. Invoice the referring practice instead, and it bills the payer; you get guaranteed payment with no denial risk, but at a negotiated rate that's typically lower.

In pathology, the work often splits, with the lab billing for the technical preparation while the physician bills for the interpretation, and the two sides have to coordinate or both claims deny as duplicates. The pricing trap is real: if fee-schedule cuts have lowered what payers reimburse but your client contracts haven't been renegotiated, you can end up performing referred testing below cost.

The compliance trap is worse, because federal anti-kickback and self-referral law restricts financial arrangements between labs and referring providers, and below-cost pricing structured to attract referrals invites fraud scrutiny. Each arrangement needs deliberate pricing review and documentation.

• Direct payer billing keeps the full rate but carries all denial risk; invoicing the referring practice trades rate for certainty
• Split pathology billing requires coordination between lab and physician or both sides' claims deny as duplicates
• Review client-billing contracts against current reimbursement so referred testing isn't quietly performed below cost
• Federal anti-kickback and self-referral rules restrict lab-to-referrer pricing; below-cost deals invite fraud scrutiny

Decoding Laboratories Pathology Billing

Medicare

• Clinical testing and pathology reads are paid off different fee schedules - billing the wrong one leaves money behind
• For tests ordered without a diagnosis Medicare recognizes, the right patient paperwork up front keeps the lab from eating the cost
• When your pathologist reads slides, the interpretation is billed separately from the technical preparation - capture both
• Many molecular tests aren't covered unless the specific test is properly registered and identified before the claim goes in
• Medicare's lab fee schedule is now tied to the private-payer rates labs report, so routine-test rates keep tightening and accuracy matters more each cycle
• Patient financial-responsibility notices only protect the lab when signed before the test is run; a form collected afterward is invalid

Medicaid

• Medicaid pays for lab work at rates that vary widely by state and often sit well below Medicare - know your margins before accepting volume
• Some states route lab benefits through managed-care plans with their own rules, so requirements have to be verified per plan
• Referred lab work requires confirming the ordering provider is properly enrolled, or the claim is denied
• Genetic and high-cost panels frequently need approval first - secure it before running the test, not after

Commercial Payers

• Many plans only pay in-network labs - confirm participation before accepting the specimen or the whole claim is lost
• Some plans steer volume to preferred lab networks that pay more, so knowing where you stand affects real revenue
• Follow-on testing triggered automatically by a first result often needs notice or approval, or the payer strips it off
• Genetic and molecular testing frequently runs through a separate benefit manager for approval - plan for that step upfront

All Payer Best Practices

• Keep clean specimen records - ordering provider, collection date, and result delivery - because incomplete records sink otherwise-payable claims
• Confirm every ordering provider is properly enrolled with the payer, since claims get denied for orders from non-enrolled providers
• Watch filing deadlines closely - specimen processing time eats into the window, and a missed deadline is a permanent loss
• Connect your lab systems to billing so orders flow into clean claims without the manual re-entry where errors start
• Track denials and underpayments by test category, not just claim count, so a small systematic error surfaces before it compounds across months of volume
• Price client-billing arrangements deliberately and review them when payer rates change, since referral pricing carries federal compliance rules as well as margin risk

Related Billing Resources

• Laboratory Billing Services
• Oncology Billing
• Internal Medicine Billing
• Plastic Surgery Billing
• Medical Coding Services